GlassScriptPhysician profile
William Anthony Ante
NPI 1518964303
$4,657.32
in general payments reported to CMS, 2019-2025
33 companies · $936 in 2025
The $936 reported for 2025 was more than what 87% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $320 · 2021: $421 · 2022: $628 · 2023: $548 · 2024: $606 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Travel and Lodging: $210 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.29 |
| Travel and Lodging | $210.45 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $821.87 | 2019-2025 | Evenity, Prolia |
| Nevro Corp. | $745.96 | 2019-2024 | Senza |
| Pacira Therapeutics, INC. | $664.40 | 2019 | |
| Horizon Therapeutics Plc | $475.80 | 2019-2022 | |
| Stryker Corporation | $396.02 | 2019-2025 | Spinejack, Optablate, Mild Device Kit |
| Globus Medical, INC. | $301.21 | 2025 | Senza, Vyrsa V1, Vyrsa V1 |
| Medtronic, INC. | $162.67 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $143.68 | 2019-2024 | |
| Medtronic USA, INC. | $111.68 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $104.57 | 2025 | |
| Sanofi-Aventis U.S. LLC | $89.13 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $86.39 | 2019-2025 | Euflexxa |
| Djo, LLC | $66.17 | 2023-2024 | Cmf, Donjoy |
| Lilly USA, LLC | $64.11 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $63.13 | 2022-2023 | Lioresal (Baclofen) |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $46.96 | 2019-2022 | |
| Orthogenrx INC. | $36.19 | 2019 | |
| Radius Health, INC. | $36.11 | 2019-2024 | Tymlos |
| Abbott Laboratories | $26.03 | 2019-2020 | |
| Innovation Technologies INC | $24.16 | 2025 | Irrisept |
| Avanos Medical | $19.44 | 2025 | Generator |
| Pacira Pharmaceuticals Incorporated | $19.35 | 2023 | Iovera, Exparel, Zilretta |
| Crossroads Orthopedics, LLC | $19.02 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.72 | 2023 | Seglentis |
| Tersera Therapeutics LLC | $16.13 | 2023 | Prialt |
| Depuy Synthes Sales INC. | $14.86 | 2024 | Monovisc |
| Convatec INC. | $13.58 | 2020 | |
| Endo Pharmaceuticals INC. | $13.27 | 2020 | |
| Athena Bioscience, LLC | $13.03 | 2024 | Qdolo |
| Relievant Medsystems, INC. | $12.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.38 | 2019 | |
| Pfizer INC. | $10.80 | 2019 | |
| Orthofix Medical, INC. | $8.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.